Detailed Information
Cited 65 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Zhu, Andrew X. | - |
| dc.contributor.author | Kang, Yoon-Koo | - |
| dc.contributor.author | Yen, Chia-Jui | - |
| dc.contributor.author | Finn, Richard S. | - |
| dc.contributor.author | Galle, Peter R. | - |
| dc.contributor.author | Llovet, Josep M. | - |
| dc.contributor.author | Assenat, Eric | - |
| dc.contributor.author | Brandi, Giovanni | - |
| dc.contributor.author | Lim, Ho Yeong | - |
| dc.contributor.author | Pracht, Marc | - |
| dc.contributor.author | Rau, Kun-Ming | - |
| dc.contributor.author | Merle, Philippe | - |
| dc.contributor.author | Motomura, Kenta | - |
| dc.contributor.author | Ohno, Izumi | - |
| dc.contributor.author | Daniele, Bruno | - |
| dc.contributor.author | Shin, Dongbok | - |
| dc.contributor.author | Gerken, Guido | - |
| dc.contributor.author | Abada, Paolo | - |
| dc.contributor.author | Hsu, Yanzhi | - |
| dc.contributor.author | Kudo, Masatoshi | - |
| dc.date.accessioned | 2021-10-21T05:13:11Z | - |
| dc.date.available | 2021-10-21T05:13:11Z | - |
| dc.date.created | 2021-10-21 | - |
| dc.date.issued | 2018-05 | - |
| dc.identifier.issn | 0732-183X | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82436 | - |
| dc.language | 영어 | - |
| dc.language.iso | en | - |
| dc.publisher | AMER SOC CLINICAL ONCOLOGY | - |
| dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
| dc.title | REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. | - |
| dc.type | Article | - |
| dc.type.rims | ART | - |
| dc.description.journalClass | 1 | - |
| dc.identifier.wosid | 000442916001582 | - |
| dc.identifier.doi | 10.1200/JCO.2018.36.15_suppl.4003 | - |
| dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.36, no.15 | - |
| dc.description.isOpenAccess | N | - |
| dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
| dc.citation.volume | 36 | - |
| dc.citation.number | 15 | - |
| dc.contributor.affiliatedAuthor | Shin, Dongbok | - |
| dc.type.docType | Meeting Abstract | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.